1 541

Cited 37 times in

Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

Authors
 Byung Kyu Park  ;  Yoon Jae Kim  ;  Jeong Youp Park  ;  Seungmin Bang  ;  Seung Woo Park  ;  Jae Bock Chung  ;  Kyung Sik Kim  ;  Jin-Sub Choi  ;  Woo Jung Lee  ;  Si Young Song 
Citation
 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.21(6) : 999-1003, 2006 
Journal Title
 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 
ISSN
 0815-9319 
Issue Date
2006
MeSH
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols* ; Biliary Tract Neoplasms/drug therapy* ; Cisplatin/administration & dosage* ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives* ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome
Keywords
biliary tract cancer ; chemotherapy ; cisplatin ; gemcitabine
Abstract
BACKGROUND: The aim of this phase II study was to determine the efficacy of gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer. METHODS: Eligibility criteria included histologically confirmed adenocarcinoma with measurable tumor in the biliary tract that was unresectable and either locally advanced or metastatic. Patients received a combination of gemcitabine (1000 mg/m(2) intravenously [IV] on days 1, 8, and 15) and cisplatin (75 mg/m(2) IV on day 1). Cycles were repeated every 28 days. Objective tumor response rates and toxicities were evaluated according to World Health Organization criteria. RESULTS: Twenty-seven patients were enrolled in the study and a total of 120 cycles of chemotherapy were administrated. Objective partial response was observed in nine (33.3%) patients, while stable disease was found in seven (25.9%) patients. The median survival time was 10.0 months and the 1-year survival rate was 36%. Median time to disease progression was 5.6 months. The most common grade 3-4 toxicities were leukopenia (25.9%), anemia (29.6%), thrombocytopenia (22.2%), and vomiting (18.5%). Only one patient was hospitalized for chemotherapy-related complications. CONCLUSION: Gemcitabine and cisplatin combination chemotherapy is an effective, safe, and well-tolerated regimen for the treatment of advanced biliary tract cancer.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2006.04230.x/abstract
DOI
10.1111/j.1440-1746.2006.04230.x
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Kyung Sik(김경식) ORCID logo https://orcid.org/0000-0001-9498-284X
Kim, Yoon Jae(김윤재)
Park, Byung Kyu(박병규)
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Song, Si Young(송시영) ORCID logo https://orcid.org/0000-0002-1417-4314
Lee, Woo Jung(이우정) ORCID logo https://orcid.org/0000-0001-9273-261X
Chung, Jae Bock(정재복)
Choi, Jin Sub(최진섭)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/109860
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links